Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- SAH +6.5%
Other news:
- ARDX +46.3% (Pivotal Phase 3 study of Tenapanor for IBS-C hits primary and all secondary endpoints to support NDA submission in 2H18)
- INFI +39.5% (announces that an abstract describing new data for IPI-549 has been selected as a late-breaking presentation during an oral session at the 2017 SITC))
- LTBR +22.5% (received a Notice of Allowance from the European Patent Office for an additional patent relating to Lightbridge's innovative metallic fuel design)
- CLNT +15.7% (enters into an exclusivity agreement with 3D Discovery)
- ONCS +14.7% (confirms acceptance of late breaking abstract at upcoming Society for Immunotherapy of Cancer Meeting November 8-12 )
- KTOV +9.2% (after 55% move higher today)
- AVXL +8.2% (announces pharmacokinetic (PK) and pharmacodynamic (PD) data for ANAVEX2-73 from its positive Phase 2a study)
- KPTI +7.7% ( signs license development and commercializing agreement with Ono Pharmaceutical in Japan and other Asian countries)
- BDSI +6.8% (entered into a Settlement Agreement with Teva )
- BW +6.6% (VIEX Capital Advisors disclosed 6.4% active stake; believes the Board must take immediate action to monetize assets and make aggressive cost reductions)
- NMIH +5.2% (to join S&P SmallCap 600)
- DXC +4.6% (DXC Technology to combine its U.S. public sector business with Veritas affiliates to create independent, publicly traded company serving U.S. government clients )
- FPRX +4.6% (announces Cabiralizumab Phase 1a/1b data abstract selected for late breaking oral presentation)
- ACLS +4% (to join S&P SmallCap 600)
- SIGM +3.8% (announces major restructuring actions to accelerate the return to profitability; strategic review ongoing)
- XL +2.9% (estimates Q3 preliminary hurricane related net losses of approx $1.33 bln and total catastrophe losses of $1.48 bln -- largely in line with co's expectations)
- ONCE +1.7% (presenting at Cellular, Tissue and Gene Therapies Advisory Committee meeting)
- DBVT +1.6% (completes blinded period in REALISE study of Viaskin Peanut; topline results expected in Novemberg)
- HMY +1.6% (reports Q1 gold production)
- ZTO +1.5% (is implementing certain increases in the prices of its delivery services)
Analyst comments:
- GLUU +5% (upgraded to Buy from Hold at The Benchmark Company)
- ADVM +1.4% (initiated with a Outperform at Raymond James )